Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Tocilizumab products are in shortage in Canada (1 of 7 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
An interleukin-6 inhibitor used to treat rheumatoid arthritis and other inflammatory conditions.
Products affected
1 / 7
Reports on file
10
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
AVTOZMA
200MG · SOLUTION · CELLTRION INC.
DIN 02562030 · since ?, no end estimate · Demand increase for the drug.
Anticipated
AVTOZMA
400MG · SOLUTION · CELLTRION INC.
DIN 02562049 · Demand increase for the drug.
Resolved
ACTEMRA
162MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02483327 · ended Dec 6, 2022 · Demand increase for the drug.
Resolved
ACTEMRA
162MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02424770 · ended Dec 6, 2022 · Demand increase for the drug.
Avoided
ACTEMRA
80MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02350092 · ended Jun 23, 2022 · Disruption of the manufacture of the drug.
Avoided
ACTEMRA
400MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02350114 · ended Jun 22, 2022 · Disruption of the manufacture of the drug.
Avoided
ACTEMRA
200MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02350106 · ended Jun 22, 2022 · Disruption of the manufacture of the drug.
Resolved
ACTEMRA
200MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02350106 · ended Dec 9, 2021 · Disruption of the manufacture of the drug.
Resolved
ACTEMRA
162MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02424770 · ended Nov 25, 2021
Avoided
ACTEMRA
162MG · SOLUTION · HOFFMANN-LA ROCHE LIMITED
DIN 02483327 · ended Nov 25, 2021
What's happening
Tocilizumab is currently affected by an active shortage report filed with Health Canada by CELLTRION INC..
The reported cause is: demand increase for the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Tocilizumab is classified under “IMMUNOSUPPRESSANTS” (ATC L04AC).
Recent changes
No changes recorded yet.
Common questions
What is Tocilizumab used for?
An interleukin-6 inhibitor used to treat rheumatoid arthritis and other inflammatory conditions.
When will Tocilizumab be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Tocilizumab in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.